tbuckley/cabot-search huggingface dataset:
Abstract 11700: Change of Exhaled Acetone Concentration Levels in Patients With Acute Decompensated Heart Failure
Authors: Tetsuro Yokokawa, Takamasa Sato, Satoshi Suzuki, Masayoshi Oikawa, Akiomi Yoshihisa, Atsushi Kobayashi, Takayoshi Yamaki, Hiroyuki Kunii, Kazuhiko Nakazato, Hitoshi Suzuki, Shu-ichi Saitoh, Takafumi Ishida, Akito Shimouchi, Yasuchika Takeishi
Journal: Circulation (2017)

Background: Although breath analysis has emerged as a noninvasive tool in several clinical conditions, it is not widely used in cardiovascular disease yet. Exhaled acetone is one of the compounds expected as biomarkers for heart failure. However, it is unknown how exhaled acetone concentration changes in clinical course of heart failure. Objective: To investigate time course of exhaled acetone concentration in acute decompensated heart failure. Methods: This study included 19 patients with acute decompensated heart failure (ADHF group), and 14 stable patients (control group). Exhaled acetone was collected from these patients and the concentration was measured with gas chromatography. Results: The ADHF group had higher heart rates (p = 0.020), higher levels of brain natriuretic peptide (p < 0.001), and blood total ketone bodies (p = 0.003), compared with the control group. In ADHF group, exhaled acetone concentration was significantly decreased after treatment (median: 2.40 ppm vs. 0.92 ppm, p < 0.001). On...
Abstract P154: Associations between DNA Methylation of Four Genes and Risk of Cardiovascular Disease in the Cardiovascular Health Study
Authors: Annette L Fitzpatrick, Nigel J Belshaw, Nancy S Jenny, Wing C Leung, Archana Shrestha, Henri S Tapp
Journal: Circulation (2013)

DNA methylation of gene regulatory regions plays an important role in modulating expression. We hypothesized that methylation of four genes selected a priori due to their relationship with cardiovascular disease (CVD) would be associated with CVD risk factors, incident CVD, and mortality. The genes were 1) Tumor Necrosis Factor (TNF) which encodes for the cytokine TNF involved in systemic inflammation; 2) Superoxide Dismutase 3 (SOD3) associated with antioxidant function; 3) Synuclein Gamma (SNCG) believed to be related to neurodegenerative diseases; and 4) Serpin A5 (SERPINA5), a serine protease inhibitor related to coagulation and inflammation. We used quantitative methylation-specific PCR to measure the methylation status of each gene at baseline and 8 years later in 492 older adults enrolled in the Cardiovascular Health Study (CHS). The CHS is a multi-site observational cohort investigating CVD in older adults initiated in 1989/90 with follow-up through the present. We evaluated associations between p...
Colonization and persistence capacity of a multi-strain probiotic in food allergy.
Authors: Maurizio Mennini, Sofia Reddel, Stefania Arasi, Federica Del Chierico, Tania Napolitano, Carla Riccardi, Vincenzo Fierro, Pamela Vernocchi, Lorenza Putignani, Alessandro G. Fiocchi
Journal: Journal of Allergy and Clinical Immunology (2019)
Sickle Cell Subjects Have a Stronger and Faster Neurally Mediated Vasoconstriction Response to Cold Pain That Correlates with Anxiety Scores
Authors: Saranya Veluswamy, Payal Shah, Maha Khaleel, Mammen Puliyel, Wanwara Thuptimdang, Patjanaporn Chalacheva, John Sunwoo, Christopher Clement Denton, Roberta Miyeko Kato, Jon A Detterich, John C Wood, Richard Sposto, Michael Khoo, Lonnie Zeltzer, Thomas D. Coates
Journal: Blood (2018)
<scp>CD</scp> 8 resident memory T cells with interleukin 17A‐producing potential are accumulated in disease‐naïve nonlesional sites of psoriasis possibly in correlation with disease duration
Authors: S. Vo, R. Watanabe, H. Koguchi‐Yoshioka, Y. Matsumura, Y. Ishitsuka, Y. Nakamura, N. Okiyama, Y. Fujisawa, M. Fujimoto
Journal: British Journal of Dermatology (2019)
The Genome of<i>Armadillidium vulgare</i>(Crustacea, Isopoda) Provides Insights into Sex Chromosome Evolution in the Context of Cytoplasmic Sex Determination
Authors: Mohamed Amine Chebbi, Thomas Becking, Bouziane Moumen, Isabelle Giraud, Clément Gilbert, Jean Peccoud, Richard Cordaux
Journal: Molecular Biology and Evolution (2019)

The terrestrial isopod Armadillidium vulgare is an original model to study the evolution of sex determination and symbiosis in animals. Its sex can be determined by ZW sex chromosomes, or by feminizing Wolbachia bacterial endosymbionts. Here, we report the sequence and analysis of the ZW female genome of A. vulgare. A distinguishing feature of the 1.72 gigabase assembly is the abundance of repeats (68% of the genome). We show that the Z and W sex chromosomes are essentially undifferentiated at the molecular level and the W-specific region is extremely small (at most several hundreds of kilobases). Our results suggest that recombination suppression has not spread very far from the sex-determining locus, if at all. This is consistent with A. vulgare possessing evolutionarily young sex chromosomes. We characterized multiple Wolbachia nuclear inserts in the A. vulgare genome, none of which is associated with the W-specific region. We also identified several candidate genes that may be involved in the sex determination or sexual differentiation pathways. The A. vulgare genome serves as a resource for studying the biology and evolution of crustaceans, one of the most speciose and emblematic metazoan groups.
A biomarker for obstructive sleep apnea in chronic rhinosinusitis
Authors: Navid Salahi, Sadafsadat Mirkarimi, Serag Fares, Christopher D. Codispoti, Phillip LoSavio, Rafsa Khan, Alejandra Lastra, Mary C. Tobin, Robert P. Schleimer, Pete Batra, Mahboobeh Mahdavinia
Journal: Journal of Allergy and Clinical Immunology (2019)
Inappropriate Use of the Term <i>Autism</i> as Analogy—Reply
Authors: Peter Louis Loper
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study
Authors: Clare J Taylor, José M Ordóñez-Mena, Andrea K Roalfe, Sarah Lay-Flurrie, Nicholas R Jones, Tom Marshall, F D Richard Hobbs
Journal: BMJ (2019)

Abstract Objectives To report reliable estimates of short term and long term survival rates for people with a diagnosis of heart failure and to assess trends over time by year of diagnosis, hospital admission, and socioeconomic group. Design Population based cohort study. Setting Primary care, United Kingdom. Participants Primary care data for 55 959 patients aged 45 and over with a new diagnosis of heart failure and 278 679 age and sex matched controls in the Clinical Practice Research Datalink from 1 January 2000 to 31 December 2017 and linked to inpatient Hospital Episode Statistics and Office for National Statistics mortality data. Main outcome measures Survival rates at one, five, and 10 years and cause of death for people with and without heart failure; and temporal trends in survival by year of diagnosis, hospital admission, and socioeconomic group. Results Overall, one, five, and 10 year survival rates increased by 6.6% (from 74.2% in 2000 to 80.8% in 2016), 7.2% (from 41.0% in 2000 to 48.2% in 2012), and 6.4% (from 19.8% in 2000 to 26.2% in 2007), respectively. There were 30 906 deaths in the heart failure group over the study period. Heart failure was listed on the death certificate in 13 093 (42.4%) of these patients, and in 2237 (7.2%) it was the primary cause of death. Improvement in survival was greater for patients not requiring admission to hospital around the time of diagnosis (median difference 2.4 years; 5.3 v 2.9 years, P&lt;0.001). There was a deprivation gap in median survival of 0.5 years between people who were least deprived and those who were most deprived (4.6 v 4.1 years, P&lt;0.001). Conclusions Survival after a diagnosis of heart failure has shown only modest improvement in the 21st century and lags behind other serious conditions, such as cancer. New strategies to achieve timely diagnosis and treatment initiation in primary care for all socioeconomic groups should be a priority for future research and policy.
The Non-Canonical, R-Loop Regulatory Function of PIWIL4 Maintains Genomic Integrity and Leukemic Potential of AML Cells
Authors: Shiva Bamezai, Naidu Vegi, Alex Pulikkottil Jose, Julia Müller, Ingrid Grummt, Chenlin Song, Konstanze Döhner, Hartmut Döhner, Michaela Feuring-Buske, Vijay Pal Singh Rawat, Christian Buske
Journal: Blood (2018)
The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q
Authors: Victoria Panagiota, Manja Meggendorfer, Anne Sophie Kubasch, Razif Gabdoulline, Jan Krönke, Rabia Shahswar, Anna Mies, Christian Kandziora, Piroska Klement, Johannes Schiller, Gudrun Göhring, Claudia Haferlach, Christina Ganster, Katayoon Shirneshan, Annika Gutermuth, Christian Thiede, Ulrich Germing, Thomas Schroeder, Guido Kobbe, Sabrina Klesse, Christian Koenecke, Brigitte Schlegelberger, Nicolaus Kroeger, Detlef Haase, Konstanze Döhner, Wolfgang R. Sperr, Peter Valent, Arnold Ganser, Felicitas Thol, Torsten Haferlach, Uwe Platzbecker, Michael Heuser
Journal: Blood (2018)
Abstract 16572: Progenitor Cells of Hypertensive CAD Patients With Heart Failure: A Principal Component Analysis Sub-Study From the CCTRN FOCUS Trial
Authors: Mahan Shahrivari, Lem Moye, Timothy D Henry, Jay H Traverse, Doris Taylor, Emerson Perin, Christopher Cogle, Mark S Segal, Carl J Pepine
Journal: Circulation (2017)

Background: Hypertension (HTN) and heart failure (HF) are associated with inflammation, as well as loss of structural integrity and functional impairment of the vasculature. Vascular progenitor cel...
Effectiveness of manual therapy in COPD: A systematic review of randomised controlled trials
Authors: C. Simonelli, M. Vitacca, M. Vignoni, N. Ambrosino, M. Paneroni
Journal: Pulmonology (2019)

Manual therapy (MT) has been proposed in pulmonary rehabilitation programmes for patients with chronic obstructive pulmonary disease (COPD), but an updated systematic review of the evidence is lacking. We aimed to systematically review the effectiveness of MT interventions, alone or added to exercise, on lung function, exercise capacity and quality of life in COPD patients, compared to other therapies (e.g. exercise alone) or no treatment.We searched MEDLINE, EMBASE, Physiotherapy Evidence Database, and Cochrane Central Register of Controlled Trials databases, using the terms: COPD, manual therapy, manipulation, joint mobilisation, osteopathic manipulation. Only randomised controlled trials (RCT) were considered.Out of 555 articles screened, 6 fulfilled the inclusion criteria. The study designs were heterogeneous (with different intervention schedules) and there was a high risk of bias. No effect on lung function was found, while results on exercise capacity were contrasting. MT had no effect on quality of life, although valid measures were available only in one study. Only mild adverse events were reported.Few RCTs of poor methodological quality are available on the effects of MT in COPD. More and better quality RCTs are needed before this technique can be included in rehabilitation programmes for these patients.
Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms
Authors: Benjamin H Durham, Estibaliz Lopez-Rodrigo, David H Abramson, Jennifer Picarsic, Alessandro Pastore, Diana Mandelker, Michael Francis Walsh, Maria E Arcila, Marc Ladanyi, David Solit, Michael F. Berger, David M. Hyman, Michelle Ki, Ira Dunkel, Frederic Geissmann, Eli L Diamond, Omar I Abdel-Wahab
Journal: Blood (2018)
Sex Differences in In-Hospital Management and Outcomes of Patients With Acute Coronary Syndrome
Authors: Yongchen Hao, Jing Liu, Jun Liu, Na Yang, Sidney C. Smith, Yong Huo, Gregg C. Fonarow, Junbo Ge, Kathryn A. Taubert, Louise Morgan, Mengge Zhou, Yueyan Xing, Chang-Sheng Ma, Yaling Han, Dong Zhao
Journal: Circulation (2019)

Coronary heart disease is a leading cause of mortality among women. Systematic evaluation of the quality of care and outcomes in women hospitalized for acute coronary syndrome (ACS), an acute manifestation of coronary heart disease, remains lacking in China. The CCC-ACS project (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) is an ongoing nationwide registry of the American Heart Association and the Chinese Society of Cardiology. Using data from the CCC-ACS project, we evaluated sex differences in acute management, medical therapies for secondary prevention, and in-hospital mortality in 82 196 patients admitted for ACS at 192 hospitals in China from 2014 to 2018. Women with ACS were older than men (69.0 versus 61.1 years, P<0.001) and had more comorbidities. After multivariable adjustment, eligible women were less likely to receive evidence-based acute treatments for ACS than men, including early dual antiplatelet therapy, heparins during hospitalization, and reperfusion therapy for ST-segment-elevation myocardial infarction. With respect to strategies for secondary prevention, eligible women were less likely to receive dual antiplatelet therapy, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, statins at discharge, and smoking cessation and cardiac rehabilitation counseling during hospitalization. In-hospital mortality rate was higher in women than in men (2.60% versus 1.50%, P<0.001). The sex difference in in-hospital mortality was no longer observed in patients with ST-segment-elevation myocardial infarction (adjusted odds ratio, 1.18; 95% CI, 1.00 to 1.41; P=0.057) and non-ST-segment elevation ACS (adjusted odds ratio, 0.84; 95% CI, 0.66 to 1.06; P=0.147) after adjustment for clinical characteristics and acute treatments. Women hospitalized for ACS in China received acute treatments and strategies for secondary prevention less frequently than men. The observed sex differences in in-hospital mortality were mainly attributable to worse clinical profiles and fewer evidence-based acute treatments provided to women with ACS. Specially targeted quality improvement programs may be warranted to narrow sex-related disparities in quality of care and outcomes in patients with ACS. URL: https://www.clinicaltrials.gov . Unique identifier: NCT02306616.
Effects on abstinence of nicotine patch treatment before quitting smoking: Parallel, two arm, pragmatic randomised trial: The preloading investigators
Authors: P Aveyard
Journal: BMJ (2018)

© Published by the BMJ Publishing Group Limited. Objective To examine the effectiveness of a nicotine patch worn for four weeks before a quit attempt. Design Randomised controlled open label trial. Setting Primary care and smoking cessation clinics in England, 2012-15. Participants 1792 adults who were daily smokers with tobacco dependence. 899 were allocated to the preloading arm and 893 to the control arm. Interventions Participants were randomised 1:1, using concealed randomly permuted blocks stratified by centre, to either standard smoking cessation pharmacotherapy and behavioural support or the same treatment supplemented by four weeks of 21 mg nicotine patch use before quitting: preloading. Main outcome measures The primary outcome was biochemically confirmed prolonged abstinence at six months. Secondary outcomes were prolonged abstinence at four weeks and 12 months. Results Biochemically validated abstinence at six months was achieved by 157/899 (17.5%) participants in the preloading arm and 129/893 (14.4%) in the control arm: difference 3.0% (95% confidence interval -0.4% to 6.4%), odds ratio 1.25 (95% confidence interval 0.97 to 1.62), P=0.08 in the primary analysis. There was an imbalance between arms in the frequency of varenicline use as post-cessation treatment, and planned adjustment for this gave an odds ratio for the effect of preloading of 1.34 (95% confidence interval 1.03 to 1.73), P=0.03: difference 3.8% (0.4% to 7.2%). At four weeks, the difference in prolonged abstinence unadjusted for varenicline use was odds ratio 1.21 (1.00 to 1.48), difference 4.3% (0.0% to 8.7%), P=0.05, and adjusted for varenicline use was 1.32 (1.08 to 1.62) P=0.007. At 12 months the odds ratio was 1.28 (0.97 to 1.69), difference 2.7% (-0.4% to 5.8%), P=0.09 unadjusted for varenicline use and after adjustment was 1.36 (1.02 to 1.80) P=0.04. 5.9% of participants discontinued preloading owing to intolerance. Gastrointestinal symptoms - chiefly nausea - occurred in 4.0% (2.2% to 5.9%) more people in the preloading arm than control arm. Eight serious adverse events occurred in the preloading arm and eight in the control arm (odds ratio 0.99, 0.36 to 2.75). Conclusions Evidence was insufficient to confidently show that nicotine preloading increases subsequent smoking abstinence. The beneficial effect seems to have been masked by a concurrent reduction in the use of varenicline in people using nicotine preloading, and future studies should explore ways to mitigate this unintended effect. Trial registration Current Controlled Trials ISRCTN33031001.
Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.
Authors: Nicola Personeni, Tiziana Pressiani, Antonio Capogreco, Arianna Dal Buono, Antonio D'Alessio, Maria Giuseppina Prete, Valeria Smiroldo, Silvia Bozzarelli, Laura Giordano, Alessio Aghemo, Armando Santoro, Lorenza Rimassa
Journal: Journal of Clinical Oncology (2019)

341 Background: In patients with hepatocellular carcinoma (HCC) and baseline liver dysfunction, hepatic immune-related adverse events (HIRAEs) during immunotherapy have not been adequately characterized and their impact on subsequent treatment outcomes is not known. Methods: 40 patients with advanced/unresectable HCC and Child Pugh score A have been enrolled in first and second-line clinical trials of anti-programmed cell death protein 1 (PD-1) monoclonal antibodies (mAbs). HCC etiologies were: hepatitis C (32.5%), hepatitis B (7.5%), alcohol abuse (27.5%), other (32.5%). 7 received anti-PD-1 mAbs alone and 33 received combined regimens that included anti-PD-1 mAbs plus either anti-cytotoxic T lymphocyte antigen 4 (30.4%) or tyrosine kinase inhibitors (TKIs) (54.5%), or both (15.1%). We reviewed their liver function tests and HIRAEs onset was related to time to treatment failure (TTF). Results: Overall, 12 patients (30%) developed grade ≥ 3 hepatitis according to Common Toxicity Criteria for Adverse Events v. 4.03, resulting in 4 cases of grade 2 drug-induced liver injury per DILI Working Group criteria. Time between therapy initiation and hepatitis onset was 1.4 months (0.4-2.8) and median peak aminotransferase (AT) level was 258 IU/L (85-869). Out of 6 permanent treatment discontinuations due to adverse events (AEs), 4 were linked to hepatitis. Higher AT median levels at baseline were significantly linked to grade ≥ 3 hepatitis compared with lower grades (95 IU/L vs. 36 IU/L, respectively; p = 0.008). Etiology, age, treatment did not predict HIRAEs onset. TTF in patients in patients with grade ≥ 3 hepatitis was shorter than in the whole cohort (1.4 vs. 3.8 months, p = 0.041), while overall survival did not differ (p = 0.125). Conclusions: We observed a 30% incidence of clinically significant HIRAEs. HIRAEs represent the most frequent AEs leading to treatment discontinuation in patients with HCC undergoing treatments with immune checkpoint inhibitors. Baseline AT levels may identify patients at increased risk of grade ≥ 3 hepatitis.
Abstract P344: Sleep Duration and Obesity: Impact of Demographics, Socioeconomic Status, Health Behaviors, and Health Status
Authors: Michael Grandner
Journal: Circulation (2018)

Introduction: Many studies have shown that sleep duration is associated with obesity. It is unclear, though, whether this relationship exists equally across groups and whether it depends on demographics, socioeconomics, or aspects of health. Methods: Nationally-representative data from the 2016 BRFSS was used. Obesity was calculated as BMI≥30. Sleep duration was categorized as very short (≤4), short (5-6), normal (7-8), and long (≥9). Covariates included demographics (age, sex, race/ethnicity, education, marital status), socioeconomics (education, income, employment, # children), health risk factors (smoking, heavy drinking, sedentary lifestyle, access to a doctor, foregoing medical care due to cost), and health status (physical health, mental health, health-related limitations). Weighted logistic regression examined 5 models (unadjusted, demographics, add socioeconomics, add health behaviors, add health status). Whether relationships depended on covariates were evaluated with interaction terms and followed up by stratified analyses. Results: See Table for associations between sleep duration and obesity across all 5 models. In all models, very short, short, and long sleep were all associated with obesity, with very short sleep carrying the greatest risk. Note that as the number of covariates increased, the analytic samples were smaller. Interaction terms for all variables were statistically significant (p&lt;0.001). Very short and short sleep effects were strongest in the youngest adults. Relationships were stronger in women. Sedentary individuals, heavy drinkers, and smokers demonstrated a weaker relationship. Lack of care was associated with a stronger relationship. Conclusions: Both short and long sleep are associated with obesity, even after accounting for many covariates. However, this relationship depends on factors such as age, sex, race/ethnicity, socioeconomic status, and health. This will help towards understanding risk and targeting interventions.
Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) potentiates postsynaptic vagal inhibition of cardiac contraction in vivo and in vitro
Authors: PB Massion, C Dessy, F Desjardins, M Pelat, X Havaux, C Belge, P Moulin, Y Guiot, O Feron, Stefan Janssens, JL Balligand
Journal: Circulation (2004)
Targeting MYC-Driven B-Cell Lymphoma By Inhibition of the Histone Methyltransferase DOT1L
Authors: Anagha Deshpande, Benson Chen, Parham Ramezani-Rad, Alessandro Pastore, Luyi Zhao, Oliver Weigert, Scott A. Armstrong, Robert C Rickert, Bing Ren, Aniruddha J. Deshpande
Journal: Blood (2018)
A Comprehensive Approach to Assessing the Value of Prophylactic Therapy for the Ultra Rare Disease Hereditary Angioedema Using Real World Patient Data
Authors: Anthony J. Castaldo, Christian Jervelund, Andreas R. Kirk, Deborah Corcoran, Henrik Balle Boysen, Janet F. Long, Sandra C. Christiansen, Bruce L. Zuraw
Journal: Journal of Allergy and Clinical Immunology (2019)
Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis
Authors: Taesik Gwag, Zhaojie Meng, Yipeng Sui, Robert N. Helsley, Se-Hyung Park, Shuxia Wang, Richard N. Greenberg, Changcheng Zhou
Journal: Journal of Hepatology (2019)